Woodford Investment Management Ltd Increases Stake in Prothena Co. PLC (PRTA)
Woodford Investment Management Ltd grew its stake in shares of Prothena Co. PLC (NASDAQ:PRTA) by 3.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,924,614 shares of the biotechnology company’s stock after purchasing an additional 367,000 shares during the quarter. Prothena makes up 21.1% of Woodford Investment Management Ltd’s portfolio, making the stock its 3rd largest holding. Woodford Investment Management Ltd owned about 29.95% of Prothena worth $173,860,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently bought and sold shares of the company. Palo Alto Investors LP grew its holdings in shares of Prothena by 0.5% during the first quarter. Palo Alto Investors LP now owns 1,101,338 shares of the biotechnology company’s stock valued at $40,430,000 after purchasing an additional 5,683 shares during the last quarter. Xact Kapitalforvaltning AB bought a new position in Prothena in the 1st quarter worth approximately $210,000. LPL Financial LLC bought a new position in Prothena in the 1st quarter worth approximately $210,000. Aperio Group LLC bought a new position in Prothena in the 1st quarter worth approximately $222,000. Finally, Oppenheimer & Co. Inc. bought a new position in Prothena in the 1st quarter worth approximately $284,000.
NASDAQ PRTA traded down $0.41 on Friday, reaching $13.39. 379,133 shares of the stock traded hands, compared to its average volume of 256,301. The firm has a market cap of $552.14 million, a P/E ratio of -3.29 and a beta of 2.88. Prothena Co. PLC has a 12 month low of $10.43 and a 12 month high of $70.00.
A number of brokerages recently issued reports on PRTA. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 price objective (up from $14.00) on shares of Prothena in a report on Friday, June 15th. BidaskClub raised Prothena from a “hold” rating to a “buy” rating in a report on Wednesday, August 15th. Zacks Investment Research lowered Prothena from a “buy” rating to a “hold” rating in a report on Tuesday, May 22nd. Barclays lowered Prothena from an “equal weight” rating to an “underweight” rating and set a $12.00 price objective for the company. in a report on Monday, May 21st. Finally, Oppenheimer reissued a “hold” rating on shares of Prothena in a report on Friday, May 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. Prothena has a consensus rating of “Hold” and an average target price of $45.91.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.